In a breakthrough for incretin medicines, Chinas National Medical Products Administration (NMPA) has approved Innovents dual GLP-1/glucagon (GCP) receptor agonist mazdutide for chronic weight management in Chinese adults who are overweight or have obesity
estimated ~41% direct, weight-loss-independent effect.) Wang L, Xu R, Kaelber DC, Berger NA
Theres clear evidence that dietary patterns and specific nutrients are vital to the mitigation of inflammation, oxidative stress/mitochondrial dysfunction, and gut dysbiosis.3 Nutrients also are necessary to support methylation, neurobiological networks, and hormone signaling pathways that modulate mood, appetite, sleep, neurogenesis, and cognitive function.16 Several metabolic actors including insulin, GABA (gamma-Aminobutyric acid), brain-derived neurotrophic factor (BDNF), and other gut hormones play roles in stress-related and affective disorders.17 Metabolic syndrome, characterized by higher levels of glucose, total and LDL cholesterol, BMI, abdominal obesity, and low HDL cholesterol, has been associated with a higher prevalence of depression compared with those without the condition
Retrieved 2013-08-26
Combination therapy also modestly improves weight, blood pressure, and lipid parameters, with reductions in body weight of approximately 11.5 kg versus SGLT2i alone, though evidence for additive effects on weight loss is inconsistent
